Thema
610
22
Recruitment Status: Authorised-recruitment may be ongoing or finished
Study Type: Interventional
22
Phase: Phase 2
8
Phase: Phase 4
8
Phase: Phase 3
6
Medical Condition: COVID-19 MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
2
Medical Condition: COVID-19 MedDRA version: 23.1Level: LLTClassification code 10084355Term: COVID-19 virus test positiveSystem Organ Class: 100000004848 MedDRA version: 23.1Level: LLTClassification code 10084437Term: COVID-19 PCR test positiveSystem Organ Class: 100000004848;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
2
Medical Condition: Confirmed Covid-19 infection by RT-PCR
2
Medical Condition: Coronavirus Disease 2019 (COVID-19)-Pneumonia MedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
2
Medical Condition: Hypertension MedDRA version: 21.1Level: LLTClassification code 10081425Term: Arterial hypertensionSystem Organ Class: 100000004866;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
2
Medical Condition: Immunization for SARS-CoV-2 MedDRA version: 20.0Level: LLTClassification code 10021433Term: ImmunizationSystem Organ Class: 100000004865;Therapeutic area: Not possible to specify
2
Medical Condition: Men and women over 40 years of age, with a diagnosis of COVID-19 infection and at least one high risk criterion.;Therapeutic area: Diseases [C] - Virus Diseases [C02]
2
Medical Condition: SARS-COV-2 Infection MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
2
Medical Condition: Severe Community Acquired Pneumonia MedDRA version: 20.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
2
Medical Condition: The main objective of this pilot trial is to evaluate the effect of metoprolol on biological correlates of benefit of this therapy (inflammatory markers in blood and bronchoalveolar mini-lavage, mini-BAL). In addition, it will study cardiopulmonary hemodynamics to assess the impact of metoprolol administration in the context of respiratory distress in COVID-19;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
2
Medical Condition: immune response to COVDI-19 vaccination ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
2